Gelonghui, January 26丨Aotai Biotech (688606.SH) announced that according to preliminary estimates by the financial department, Hangzhou Aotai Biotechnology Co., Ltd. is expected to achieve operating income of 747 million yuan to 757 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease 2631.57 million yuan to 2641.57 million yuan, a year-on-year decrease of 77.66% to 77.96%. Net profit attributable to the owners of the parent company is expected to be achieved in 2023 of 165 million yuan to 175 million yuan. Compared with the same period of the previous year (statutory disclosure data), it will decrease by 1.09.48 million yuan to 1,019.48 million yuan, a year-on-year decrease of 85.23% to 86.07%. In 2023, net profit attributable to owners of the parent company after deducting non-recurring profit and loss is expected to be RMB 115 million to RMB 125 million. Compared with the same period of the previous year (statutory disclosure data), it will decrease by RMB 1,035.5 million to RMB 1045.5 million, a year-on-year decrease of 89.23% to 90.09%.
During the reporting period, the company's revenue and net profit declined, mainly due to changes in domestic and international public health prevention and control policies, a sharp decline in global demand for COVID-19 antigen detection reagents, and a decline in sales revenue related to COVID-19 antigen testing products. In 2023, according to changes in the external market environment, the company closely expanded its customers around “market research+R&D registration”, continued to consolidate its first-mover advantage in R&D in the industry, and do a good job of deep grafting between old and new customers and new products. The sales revenue of the company's conventional products (excluding COVID-19 single test products) continued to maintain a steady growth of more than 20%.